CLYM Climb Bio, Inc.: institutional ownership and insider trading
117 funds reported holding $743M of Climb Bio, Inc. in their latest 13F filings; in Q2 2026 funds net bought $313M, with 51 new positions and 22 funds selling out; over the last 12 months insiders bought $780K and sold $2.65M on the open market.
CLYM revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$13.5M, EPS -0.18
- Quarter ended Mar 31, 2026: revenue n/a, net income −$13.7M, EPS -0.20
- Quarter ended Dec 31, 2025: revenue n/a, net income −$17.5M, EPS -0.25
- Quarter ended Sep 30, 2025: revenue n/a, net income −$12.9M, EPS -0.19
Famous investors holding CLYM
- Ken Griffin (Citadel Advisors): $16.9M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $11.8M, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $2.51M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $1.93M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $376K, 0.0% of the portfolio
Largest institutional holders of CLYM
- RA CAPITAL MANAGEMENT, L.P. — $147M
- FMR LLC — $88.5M
- UBS Group AG (UBS) — $44.4M
- BRAIDWELL LP — $36.5M
- ADAGE CAPITAL PARTNERS GP, L.L.C. — $32.7M
- BlackRock, Inc. (BLK) — $30.7M
- PRICE T ROWE ASSOCIATES INC /MD/ — $27.7M
- Cormorant Asset Management, LP — $27.5M
- FRONTIER CAPITAL MANAGEMENT CO LLC — $25.3M
- VANGUARD CAPITAL MANAGEMENT LLC — $22.2M
Recent CLYM insider trades
- Sep 15, 2026: Thomas Stephen Basil sold 100,000 shares ($1.37M)
- Jun 29, 2026: Brennan Aoife sold 30,902 shares ($407K)
- Feb 26, 2026: Thomas Stephen Basil sold 50,000 shares ($350K)
- Feb 13, 2026: Thomas Stephen Basil sold 100,000 shares ($529K)
5%+ owners
- RA Capital Management, L.P.: 33.0% (Schedule 13D/A, filed Jul 7, 2026)
- FMR LLC: 11.9% (Schedule 13G, filed Jul 8, 2026)